Who
Eduardo Rene Salas
Director
Company insider
Files Form 4 as: Director, ADMA Biologics; Director, Intra-Cellular Therapies.
In numbers
- Trades disclosed
- 21
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 20 Apr 2022
- Last trade
- 9 Feb 2026
- Last filed
- 11 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Feb 2026filed 11 Feb 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Code A | —10,690 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,730 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,730 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Code A | —10,690 at $0.00 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —16,757 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —7,009 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —4,322 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —2,951 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapies | SEC FORM 4 Code D | $207K1,567 at $132.00 | filing |
| 19 Feb 2025filed 21 Feb 2025 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,279 at $0.00 | filing |
| 19 Feb 2025filed 21 Feb 2025 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Code A | —10,889 at $0.00 | filing |
| 30 Dec 2024filed 2 Jan 2025 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,011 at $0.00 | filing |
| 23 Jun 2024filed 25 Jun 2024 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code M | —1,567 at $0.00 | filing |
| 23 Jun 2024filed 25 Jun 2024 | Intra-Cellular Therapies | SEC FORM 4 Code M | —1,567 | filing |
| 14 Jun 2024filed 18 Jun 2024 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code A | —2,951 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code A | —4,322 at $0.00 | filing |
| 23 Jun 2023filed 27 Jun 2023 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code A | —1,567 at $0.00 | filing |
| 23 Jun 2023filed 27 Jun 2023 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code A | —7,009 at $0.00 | filing |
| 9 Jun 2022filed 13 Jun 2022 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code A | —16,757 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.